IL CONSIGLIO DI AMMINISTRAZIONE DI ULISSE BIOMED APPROVA IL PROGETTO DI BILANCIO CHIUSO AL 31 DICEMBRE 2021 THE BOARD OF DIRECTORS OF ULISSE BIOMED APPROVES THE DRAFT FINANCIAL STATEMENTS AT DECEMBER 31ST 2021

FINANCIAL HIGHLIGHTS ▪ REVENUE EQUAL TO EURO 19,6M VERSUS EURO 9,2M AS OF 31 DECEMBER 2020 +113% ▪ RECURRING REVENUE EQUAL TO 95% OF THE TOTAL REVENUE: - “INFRASTRUCTURE AS A SERVICE” (IAAS) REVENUE EQUAL TO EURO 9,3M VERSUS EURO 2,8M AS OF 31 DECEMBER 2020 +227% - “PLATFORM AS A SERVICE” (PAAS) REVENUE EQUAL TO EURO 7,2M VERSUS EURO 5M AS OF 31 DECEMBER 2020 +43% - “SOFTWARE AS A SERVICE” (SAAS) REVENUE EQUAL TO EURO 288K VERSUS EURO 157K AS OF 31 DECEMBER 2020 + 83% - “DATACENTER & NETWORKING” REVENUE EQUAL TO EURO 1,7M VERSUS EURO 389K AS OF 31 DECEMBER 2020 +349% ▪ EBITDA EQUAL TO EUR